EP3322731
AÐFERÐ VIÐ AÐ MEÐHÖNDLA KRABBAMEIN MEÐ ÓNÆMISÖRVANDI LYFI; MÓTEFNI SEM BINST VIÐ STÝRÐAN FRUMUDAUÐA-1 VIÐTAKA (PD-1) EÐA STÝRÐAN FRUMUDAUÐA BINDIL 1 (PD-L1)
Status:
EP Einkaleyfi ógilt eftir andmæliEP appl. date:
14.7.2016EP published:
13.1.2021EP application number:
16744626.9
EP translation filed:
10.3.2021Grant published:
15.4.2021EPO information:
European Patent Register
Max expiry date:
13.7.2036Expiry date:
13.7.2026
Title:
METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR; ANTIBODY THAT BINDS TO PROGRAMMED DEATH-1 RECEPTOR (PD-1) OR PROGRAMMED DEATH LIGAND 1 (PD-L1)
Timeline
Today
14.7.2016EP application
13.1.2021EP Publication
10.3.2021Translation submitted
15.4.2021Registration published
13.7.2026Expires
Owner
Name:
Bristol-Myers Squibb CompanyAddress:
Route 206 and Province Line Road, Princeton, NJ 08543, US
Inventor
Name:
MANEKAS, DemetriosAddress:
Howell, New Jersey 07731, US
Name:
GROSSO, JosephAddress:
Princeton, New Jersey 08543, US
Name:
ANDERSON, JeffreyAddress:
Princeton, New Jersey 08543, US
Agent
Name:
G.H. Sigurgeirsson ehf.Address:
Borgartúni 26, 105, Reykjavík,
Priority
Number:
201562192396 PDate:
14.7.2015Country:
US
Classification
Categories:
C07K 16/28, A61K 39/395, G01N 33/574, C12Q 1/6886, A61K 39/00, A61P 35/00, C12Q 1/70
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 8.6.2021
Expires: 13.7.2022
Payer: Árnason Faktor ehf.
Number: 7
Paid: 9.6.2022
Expires: 13.7.2023
Payer: Árnason Faktor ehf.
Number: 8
Paid: 11.6.2023
Expires: 13.7.2024
Payer: Árnason Faktor ehf.
Number: 9
Paid: 6.6.2024
Expires: 13.7.2025
Payer: Árnason Faktor ehf.
Number: 10
Paid: 7.7.2025
Expires: 13.7.2026
Payer: Árnason Faktor ehf.